On September 1, JOINN fell 5.07% in regular trading, trading at HK$23.22/share, with turnover of approximately HK$72.07 million. The stock extended its post-earnings selloff as investors continued to question the sustainability of its headline profit growth.

On August 28, JOINN reported H1 results showing attributable net profit of RMB 748 million, surging 1,126.8% year-over-year, while revenue came in at RMB 704 million, up only 5.27%. The dramatic profit increase was primarily driven by fair value changes in biological assets, which contributed approximately RMB 703–777 million in net profit. Stripping out this non-cash item, the company's laboratory services and other operations posted a net loss of RMB 36.6 million, indicating the core business remains unprofitable. Despite in-hand orders reaching RMB 3.7 billion (up 60.9%) and new orders of RMB 2.02 billion (up 98.0%), the market appears to be discounting gains derived from asset revaluation rather than operational improvement.

Notably, within the Life Sciences Tools and Services sector, JOINN significantly underperformed peers on the same day, with GenScript Biotech rising 7.56%, Insilico Medicine up 4.39%, and WuXi Biologics gaining 2.33%, highlighting the market's independent pricing of JOINN's earnings quality concerns.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)